Publications
Specialty
Search
Wound Care
06/12/2024
A 2,270-patient multicenter observational trial evaluating the short-term clinical impact of UrgoClean Ag on the wound healing process was published. The study demonstrates a reduction in wound size and exudate level across a range of wound types. SAWC Spring 2024 Poster CR-011
Wound Care
06/12/2024
An 85-patient 2-part RCT will examine the efficacy of Dermacyte amniotic wound care matrix for the treatment of DFUs vs SoC with primary outcome of wound closure at 12 weeks. Not yet recruiting; the estimated study completion is May 2025. clinicaltrials.gov
Wound Care
06/12/2024
Avita achieves a milestone with the first US burn center to treat a patient using its RECELL GO System. The product is a next-generation autologous cell harvesting device that uses a patient’s own skin to treat thermal burn wounds and full-thickness skin defects.
Wound Care
06/12/2024
Mölnlycke is partnering with Yuncture, an entrepreneurial incubator, to identify and collaborate with start-ups through the “Yuncture incubator program.” The partnership will run from Sept 2024 to Jan 2025.
Wound Care
06/12/2024
Case series with OptiView Transparent Gel Dressing reported a 74.9% average reduction in deep-tissue pressure injury wound area. The average time to wound closure that completely healed after dressing application was 18.3 days. SAWC Spring 2024 Poster CR-054
Wound Care
06/12/2024
StimLabs announces IRB approval for CAMPSTIM, the largest RCT trial to demonstrate the efficacy of multiple placental-based tissue products for treatment of hard-to-heal DFUs. CAMPSTIM will evaluate at least four CAMPs (Enverse, Revita, Relese and Cogenex) and enroll 272 patients in the US.
Wound Care
06/12/2024
A 60-patient RCT found that Altrazeal transforming powder dressing (TPD) was associated with higher healing rates, shorter duration of healing, less pain, and decreased dressing changes compared to current SOC in the treatnebt of CVUs. SAWC Spring 2024 Poster CR-001
Wounds
06/12/2024
The first episode of the June WCW explores cellular, acellular, and matrix products to heal wounds. Join host Dr Jonathan Johnson and guest speaker Dr Naz Wahab as they discuss advances in wound care techniques and dive into differences between the products, including best practices for application!
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/12/2024
The Siegel valve represents several firsts in TAVR: 8 French delivery sheath allowing less invasive procedures and broader patient access, particularly for women; the only nickel-free THV allowing treatment of the 20% of Americans suffering from nickel allergies; precise delivery due to lack of foreshortening and intrinsic commissural alignment; dry porcine pericardial leaflets with anti-calcification treatment and with the valve pre-mounted on the balloon.
Vascular Disease Management, CardioVascular, Journal of Invasive Cardiology
06/12/2024
BATON ROUGE, LA – Dr. Garland Green, interventional cardiologist at Cardiovascular Institute of the South (CIS), is the first in Louisiana to use the new generation Diamondback 360 Precision™ Orbital Atherectomy System (OAS) to treat coronary artery blockages. The first procedure took place in the cath lab at Baton Rouge General.
Integrated Healthcare Executive
06/12/2024
Health care security leaders facing cybersecurity threats and staffing shortages turn to outsourcing managed security services to protect patient data and mitigate risks, as highlighted in the 2024 CDW Cybersecurity Report.
EP Lab Digest
06/12/2024
Miguel Leal, MD, and Robert Schaller, DO, discuss current and evolving indications of lead extraction, as well as how to establish a relationship with the CT surgical team, prepare for complications, and mitigate risk during high-risk cases.
EMSWorld
06/12/2024
Medix Specialty Vehicles's new 7,000-square-foot paint plant will attach to the existing 10,000-square-foot paint plant and will double the paint capacity, enhance production efficiency, and address current manufacturing constraints.
EMSWorld
06/12/2024
The Canadian EMS sector will receive a major impetus for growth due to the long-awaited decision from the national government to spend an additional CAD$200 billion in healthcare over the next decade.
First Report Managed Care, Population Health
06/12/2024
Value-based care (VBC) models aim improve clinical outcomes and reduce health care costs by proactively focusing on patient wellness. To make this preventive approach to individual and population care work, patients, providers, payers, and other stakeholders, such as community-based organizations (CBOs) that offer wellness-related services, must be able to collaborate. In this commentary, experts outline the suggested requirements for proper contract management to ensure value-based care.
Advances in Inflammatory Bowel Disease Network
06/12/2024
Dr Frank Farraye, director of the IBD Center at Mayo Jacksonville, joins IBD Drive Time hosts Millie Long, MD, and Raymond Cross, MD, to review the best of presentations on the natural history of IBD at the European Crohn's & Colitis Organization meeting held earlier this year.
The Dermatologist
06/12/2024
SiSaf Ltd announced positive topline results from a phase II clinical trial of a licensee's topical treatment for mild to moderate alopecia areata (AA).
EP Lab Digest
06/11/2024
In this discussion, Mark Link, MD, and Rachel Lampert, MD, discuss the newly released 2024 HRS expert consensus statement on arrhythmias in the athlete.
Vascular Disease Management, CardioVascular, Journal of Invasive Cardiology
06/11/2024
HOUMA, LA— Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to treat a patient using the new FDA-approved Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system, a minimally-invasive alternative to open-heart surgical aortic valve replacement. Dr. Peter Fail, Dr. Shane Prejean, Dr. Deborah McCollum were the first to perform the procedure on June 11 in the hybrid operating room at Terrebonne General.
The Dermatologist
06/11/2024
At the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference, Arcutis Biotherapeutics, Inc., unveiled new findings from the INTEGUMENT-OLE long-term open-label study of roflumilast cream 0.15% for adults and children with atopic dermatitis (AD).